Thermo Fisher Scientific

Your educational resource for biopharma, pharma, environmental, food and agriculture, industrial, and clinical labs

  • Categories
    • Advancing Materials
    • Advancing Mining
    • AnalyteGuru
    • Analyzing Metals
    • Ask a Scientist
    • Behind the Bench
    • Biotech at Scale
    • Clinical Conversations
    • Examining Food
    • Identifying Threats
    • Illuminating Semiconductors
    • Life in Atomic Resolution
    • Life in the Lab
    • OEMpowered
    • The Connected Lab
  • About Us
  • Contact
Accelerating ScienceAnalyteGuru / Biopharmaceutical / Take a Step Closer to Unlocking Full Potential of AAV Gene Therapy – Download the Poster

Take a Step Closer to Unlocking Full Potential of AAV Gene Therapy – Download the Poster

By Lizzie Gallagher, Market Development Manager, Pharma and BioPharma, Thermo Fisher Scientific 12.04.2023

This is the third in a five-part BioPharma Blog Series.

Discover the critical role of AAV capsid viral proteins (VPs) in gene therapy and how they impact immunogenicity and tissue tropism. To ensure the safety, quality, and efficacy of AAV products, it is essential to understand and characterize these viral proteins, including their truncated forms and post-translational modifications (PTMs).

Previously, multiple LC-MS/MS approaches, such as intact, top-down, and peptide mapping, utilizing the Thermo Scientific™ Orbitrap Exploris™ 480 MS have been applied. With these techniques, successful identification of multiple potential phosphorylation was achieved However, due to the high sequence overlaps of VP1 and VP2, accurately localizing the phosphorylation sites can prove challenging, using the peptide mapping approach alone.

But now, with the Orbitrap Ascend Tribrid MS, it is possible to revolutionize the analysis of intact proteins by enabling multiple fragmentation techniques and higher ion transfer efficiency for high m/z ions. This state-of-the-art platform provides an ideal solution for top-down analysis, ensuring precise phosphosite localization.

In our latest study, which was recently presented at a US-based conference, we have taken targeted top-down analyses to the next level. Leveraging EThcD, HCD, and UVPD on the powerful Orbitrap Ascend Tribrid MS, we have achieved unprecedented accuracy in phosphosite localization of VP2 and confirmed the protein sequence of VP3 clip. To enhance the targeted precursor ion selection, we also conducted an additional intact protein analysis.

Download our comprehensive poster now and gain access to detailed information on our research methodologies and results.  Stay ahead in the field of gene therapy and ensure the success of your AAV products with our innovative approaches.

Don’t miss out on this opportunity, Click to download our poster and take a step closer to unlocking the full potential of AAV gene therapy using the Orbitrap Ascend Tribrid MS!

Related information

Blog 1: Revolutionizing Host Cell Protein Detection and mAb Analysis in Biopharmaceuticals
Blog 2: Poster Series: A Journey into the World of Biopharma Column Chemistry
Blog 4: Unlocking the Future of Medicine: Exploring Therapeutic Oligonucleotides
Blog 5: Unveiling Hidden Impurities: LC-HRMS for Biopharmaceutical Analysis
Download our conference posters to see how we applied advanced analytical technology to achieve the best results for oligonucleotide analysis

On LinkedIn? Visit our LinkedIn page #biopharmaceutical #orbitrap

Innovation in Biopharma analysis image

Scaling Up Biopharmaceutical Characterization with the Orbitrap Ascend BioPharma Tribrid Mass Spectrometer

Biopharmaceutical pipelines are expanding rapidly, with incr...

Read More
freedom to fragment

Radical-based Ion Activation and Dissociation

Electron Transfer Dissociation (ETD) has been commercialized...

Read More
AAV-SEC Analysis: Top 3 Takeaways From the Latest Article

AAV-SEC Analysis: Top 3 Takeaways From the Latest Article

What is the best column for separating AAV size variants? Th...

Read More
Imaging Large Multiprotein Complexes Using Native Nano DESI Mass Spectrometry

Imaging Large Multiprotein Complexes Using Native Nano DESI Mass Spectrometry

Prof. Helen Cooper, Ph.D., an expert analytical chemist from...

Read More

Lizzie Gallagher

Lizzie Gallagher is a market development manager for the pharma and biopharma market at Thermo Fisher Science, having spent a number of years in both industry, and sales and marketing. Lizzie has widespread experience with the challenges and trends of the biopharma and pharma market.
Are you Still Preparing Your GC Calibration Standards Manually?  
USP Chapter <621>: Chromeleon CDS Flexibility Simplifies Calculation of Updated Values

Privacy StatementTerms & ConditionsLocationsSitemap

© 2026 Thermo Fisher Scientific. All Rights Reserved.

Talk to us